KR20240117133A - 메닌-mll 상호작용의 저해제 - Google Patents

메닌-mll 상호작용의 저해제 Download PDF

Info

Publication number
KR20240117133A
KR20240117133A KR1020247022800A KR20247022800A KR20240117133A KR 20240117133 A KR20240117133 A KR 20240117133A KR 1020247022800 A KR1020247022800 A KR 1020247022800A KR 20247022800 A KR20247022800 A KR 20247022800A KR 20240117133 A KR20240117133 A KR 20240117133A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
formula
solvate
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022800A
Other languages
English (en)
Korean (ko)
Inventor
루벤 아바그얀
블라디슬라프 제노노비치 파친스키
니콜라이 사브추크
알렉상드르 바실리예비치 이바시첸코
알렉산더 크왓
Original Assignee
발라 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 발라 테라퓨틱스 인코포레이티드 filed Critical 발라 테라퓨틱스 인코포레이티드
Priority to KR1020257029621A priority Critical patent/KR20250135350A/ko
Publication of KR20240117133A publication Critical patent/KR20240117133A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247022800A 2021-12-09 2022-12-09 메닌-mll 상호작용의 저해제 Pending KR20240117133A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257029621A KR20250135350A (ko) 2021-12-09 2022-12-09 메닌-mll 상호작용의 저해제

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163287716P 2021-12-09 2021-12-09
US63/287,716 2021-12-09
US202263306399P 2022-02-03 2022-02-03
US63/306,399 2022-02-03
US202263397322P 2022-08-11 2022-08-11
US63/397,322 2022-08-11
PCT/US2022/052404 WO2023107696A2 (en) 2021-12-09 2022-12-09 Inhibitors of menin-mll interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257029621A Division KR20250135350A (ko) 2021-12-09 2022-12-09 메닌-mll 상호작용의 저해제

Publications (1)

Publication Number Publication Date
KR20240117133A true KR20240117133A (ko) 2024-07-31

Family

ID=86731242

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247022800A Pending KR20240117133A (ko) 2021-12-09 2022-12-09 메닌-mll 상호작용의 저해제
KR1020257029621A Pending KR20250135350A (ko) 2021-12-09 2022-12-09 메닌-mll 상호작용의 저해제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257029621A Pending KR20250135350A (ko) 2021-12-09 2022-12-09 메닌-mll 상호작용의 저해제

Country Status (11)

Country Link
US (2) US20250163061A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444300A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024545184A (cg-RX-API-DMAC7.html)
KR (2) KR20240117133A (cg-RX-API-DMAC7.html)
CN (1) CN118647378A (cg-RX-API-DMAC7.html)
AU (2) AU2022405438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240074A1 (cg-RX-API-DMAC7.html)
JO (1) JOP20240130A1 (cg-RX-API-DMAC7.html)
MX (2) MX2024007069A (cg-RX-API-DMAC7.html)
TW (1) TW202529770A (cg-RX-API-DMAC7.html)
WO (1) WO2023107696A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202529770A (zh) * 2021-12-09 2025-08-01 美商巴拉療法公司 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
TW202529770A (zh) * 2021-12-09 2025-08-01 美商巴拉療法公司 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑

Also Published As

Publication number Publication date
JP2024545184A (ja) 2024-12-05
JOP20240130A1 (ar) 2024-06-10
US20260022120A1 (en) 2026-01-22
CA3240074A1 (en) 2023-06-15
US20250163061A1 (en) 2025-05-22
KR20250135350A (ko) 2025-09-12
CN118647378A (zh) 2024-09-13
WO2023107696A3 (en) 2023-07-27
AU2022405438A1 (en) 2024-06-20
AU2025230651A1 (en) 2025-09-25
EP4444300A4 (en) 2026-03-18
MX2024007069A (es) 2024-08-22
TW202529770A (zh) 2025-08-01
JP2025170331A (ja) 2025-11-18
MX2025012108A (es) 2025-11-03
WO2023107696A2 (en) 2023-06-15
EP4444300A2 (en) 2024-10-16
TW202337435A (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
AU2022200741B2 (en) Aminothiazole compounds as c-Kit inhibitors
CA2976741C (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN101356172B (zh) 激酶抑制剂
KR102429419B1 (ko) Rho-키나아제 억제제로서 티로신 아마이드 유도체
CN105829307B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
AU2019283921A1 (en) Indole carboxamide compounds useful as kinase inhibitors
CN115867346B (zh) 激酶抑制剂
CN107074812B (zh) 取代的嘧啶化合物
JP2026504821A (ja) Ｎｌｒｐ３阻害剤としての有機化合物
AU2023249498B2 (en) Lrrk2 inhibitors
WO2022131741A1 (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도
WO2022107919A1 (ko) N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
JP2025170331A (ja) メニン－ｍｌｌ相互作用の阻害剤
JP2024539633A (ja) 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用
WO2022245085A1 (ko) 헤테로아릴 유도체 화합물 및 이의 용도
TW202517653A (zh) 治療自體免疫疾病之大環
WO2024107658A2 (en) Inhibitors of tyk2
WO2023064164A1 (en) Chimeric compounds useful in treating diseases
JP2025507758A (ja) Ｍａｌｔ１のｐｒｏｔａｃｓ
EP4444313A1 (en) Inhibitors of menin-mll interaction
WO2025175264A1 (en) Inhibitors of cdk2

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000